

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Agnew, Brian) Confirmation No.: 9818
Serial No.: 10/821,522) Examiner: Fiona Powers
Filing Date: April 19, 2004) Group Art Unit: 1626
For: COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES) Customer No.: 23358
) Attorney Docket No.: IVGN 705.2 CIP
)
)
) <u>Information Disclosure Statement</u>

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR 1.114 the Information Disclosure Statement being transmitted herewith is being filed with a Request for Continued Examination. Under 37 CFR 1.97 an information disclosure statement shall be considered if filed by the applicant before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R § 1.114. Accordingly, it is believed that no fees are required with the filing of this Supplemental IDS. However, if this is incorrect and additional fees are due then the Patent Office is authorized to deduct any requisite fees from, or deposit any overpayment to, **Deposit Account 50-3994**.

The cited references may be material to the examination of the above-identified application. Applicants respectfully request that the listed references be considered by the Examiner and be made of record in the above-identified application. The Examiner is requested to initial and return the accompanying PTO/SB08 form(s) in accordance with MANUAL OF PATENT EXAMINING PROCEDURES (MPEP) § 609.

This Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98 is not to be construed as a representation that: (1) a search has been made or (2) the information provided herein constitutes prior art to the subject invention. Accordingly, it is requested that the Examiner consider the cited references and/or materials.

This Information Disclosure Statement pursuant to 37 CFR 1.97 is not to be construed as a representation that: (1) a search has been made; (2) the above information constitutes prior art to the subject invention. Accordingly, it is requested that the Examiner consider the cited references.

The Examiner is respectfully requested to contact the undersigned if there are questions or concerns regarding this communication.

Respectfully submitted,

Date: March 12, 2008

/Koren J. Anderson/
Koren J. Anderson, Reg. No. 51,061

Invitrogen Corporation
Customer No. 23358
Phone: (541) 335-0203
Facsimile: (541) 335-0354